Chemo-genomic interrogation reveals JAK sensitive subgroup in AML
Chemo-genomic interrogation reveals JAK sensitive subgroup in AML
The role of AKT in chronic lymphocytic leukaemia transformation to Richter's syndrome
Advances in first line treatment options for MCL patients
Targeted genome editing in haematopoeitic stem cells
A microRNA driver of B-cell leukaemia
The latest in CLL from EHA 2016
Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo
Meta-analysis of overall survival in multiple myeloma treated with lenalidomide
Risk adapted therapy for acute myeloid leukaemia
Clinical characteristics and prognostic factors of plasmablastic lymphoma patients
Blinatumomab improves survival of relapsed B-cell leukaemia
SGN-CD33A combined with HMA therapy produces high remission rates among older patients with AML